Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Baloxavir Marboxil; Drug
Lead sponsor: Tricore, Inc; Other
Eligibility: 5 Years and older
Enrollment: 25 participants
Timeline: 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Avian Influenza, Influenza Immunisation
Interventions: Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more

Conditions: Smoke Exposure, Influenza
Interventions: LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure); Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 49 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Human Influenza
Interventions: Recombinant Influenza Vaccine, Inactivated Influenza Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 254,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza
Interventions: Subjects were administered NasoVAX high dose; Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: PNAG-expressing Pathogenic Microbes Vaccine
Interventions: AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3, AV0328 - Cohort 4; Biological
Lead sponsor: Alopexx Vaccine, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions: artus Influenza A/B RT-PCR Test; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more

Conditions: Pneumococcal Disease
Interventions: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 1,796 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah

Conditions: Influenza
Interventions: Placebo, Favipiravir; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pandemic H5N1 Influenza
Interventions: Adjuvanted H5N1 pandemic influenza vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 662 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Miami, Florida • Newton, Kansas • Wichita, Kansas + 6 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections
Interventions: H1N1 vaccination; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza Vaccine
Interventions: Sing2016 M2SR H3N2 influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: Avonex; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Influenza
Interventions: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more

Conditions: Influenza, Human
Interventions: KT07 Capsule, Placebo; Drug · Other
Lead sponsor: Yiling Pharmaceutical Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 81
States / cities: Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more

Conditions: Pregnancy, Influenza
Interventions: Quadrivalent Influenza Vaccine (QIV); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: San Diego, California • Albany, New York • Columbus, Ohio + 2 more

Conditions: Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola, Unknown Respiratory Viruses
Interventions: Poly-ICLC; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: AVI-7100, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Search by objective public record fields.

Evaluation of a Screen and Treat Protocol for Influenza

H5N1 With or Without Topical Aldara in Healthy Adults

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Study of the Safety and Immunogenicity of NasoVAX Extension

A Study of AV0328 Administered to Healthy Adult Volunteers

Collection and Testing of Respiratory Samples

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Inpatient Influenza Surveillance

H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

A Clinical Trial of KT07 Capsule in the U.S.A

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

Safety Study of Single Administration Intravenous Treatment for Influenza

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively